Eli Lilly And Co (NYSE:LLY) Hits New 52-Week High at $141.97

Shares of Eli Lilly And Co (NYSE:LLY) reached a new 52-week high during trading on Thursday . The stock traded as high as $141.97 and last traded at $140.90, with a volume of 115672 shares traded. The stock had previously closed at $141.11.

LLY has been the subject of several recent analyst reports. UBS Group lowered their target price on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a research note on Thursday, October 17th. TheStreet raised shares of Eli Lilly And Co from a “c+” rating to a “b-” rating in a research note on Friday, November 8th. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly And Co from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Morgan Stanley raised shares of Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $116.00 to $150.00 in a research note on Wednesday, December 18th. They noted that the move was a valuation call. Finally, Bank of America initiated coverage on shares of Eli Lilly And Co in a research note on Wednesday, October 16th. They set a “buy” rating and a $133.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Eli Lilly And Co presently has an average rating of “Buy” and an average price target of $135.67.

The company’s 50 day moving average price is $127.65 and its 200-day moving average price is $115.42. The company has a market capitalization of $135.04 billion, a PE ratio of 25.43, a PEG ratio of 1.84 and a beta of 0.20. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 4.09.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 23rd. The company reported $1.48 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.43 by $0.05. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. The company had revenue of $5.48 billion during the quarter, compared to analysts’ expectations of $5.50 billion. During the same period in the previous year, the company earned $1.39 EPS. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. As a group, analysts predict that Eli Lilly And Co will post 5.8 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 14th will be issued a dividend of $0.74 per share. This is a positive change from Eli Lilly And Co’s previous quarterly dividend of $0.65. The ex-dividend date is Thursday, February 13th. This represents a $2.96 annualized dividend and a dividend yield of 2.10%. Eli Lilly And Co’s payout ratio is presently 46.49%.

In related news, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly And Co stock in a transaction on Monday, January 13th. The shares were sold at an average price of $138.92, for a total transaction of $28,478,600.00. Following the transaction, the insider now owns 113,741,549 shares in the company, valued at approximately $15,800,975,987.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Joshua L. Smiley bought 929 shares of Eli Lilly And Co stock in a transaction that occurred on Friday, October 25th. The shares were acquired at an average price of $107.59 per share, for a total transaction of $99,951.11. Following the acquisition, the chief financial officer now directly owns 31,524 shares in the company, valued at approximately $3,391,667.16. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 8,405 shares of company stock worth $909,004 and have sold 1,780,504 shares worth $219,697,912. Insiders own 0.11% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. Lido Advisors LLC grew its holdings in shares of Eli Lilly And Co by 64.4% during the second quarter. Lido Advisors LLC now owns 4,842 shares of the company’s stock worth $536,000 after buying an additional 1,897 shares during the last quarter. A.R.T. Advisors LLC purchased a new position in shares of Eli Lilly And Co during the second quarter worth about $2,448,000. Sterling Capital Management LLC grew its holdings in shares of Eli Lilly And Co by 0.4% during the second quarter. Sterling Capital Management LLC now owns 52,199 shares of the company’s stock worth $5,783,000 after buying an additional 222 shares during the last quarter. Gladstone Institutional Advisory LLC purchased a new position in shares of Eli Lilly And Co during the second quarter worth about $205,000. Finally, Institutional & Family Asset Management LLC grew its holdings in shares of Eli Lilly And Co by 3.0% during the second quarter. Institutional & Family Asset Management LLC now owns 26,455 shares of the company’s stock worth $2,931,000 after buying an additional 766 shares during the last quarter. Institutional investors and hedge funds own 76.45% of the company’s stock.

Eli Lilly And Co Company Profile (NYSE:LLY)

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: What does the Producer Price Index (PPI) tell investors?

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.